ARDX - Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference | Benzinga
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
Title: Efficacy of Tenapanor in Patients with Irritable Bowel Syndrome With Constipation (IBS-C): A Posthoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription Medications From the Phase 3 T3MPO-1 and T3MPO-2 Studies
Authors: Eric Shah, Brian Lacy, Yang Yang, Susan Edelstein, David Rosenbaum
Poster Number: Tu1658
Date/Time: May 21, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4)
Title: Comparing the Efficacy of Tenapanor in Irritable Bowel Syndrome with Constipation in Hispanic vs Non-Hispanic Patients: A Posthoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies
Authors: Rosita Frazier, William Hasler, Yang Yang, Susan Edelstein, David Rosenbaum
Poster Number: Tu1663
Date/Time: May 21, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4)
In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: "Discover IBSRELA: a Different Mechanism of Action to Treat Adults With IBS-C: A Case-Based Discussion," on May 19, 2024, from 2:30-3:15 PM EDT, where Brooks Cash, MD, will lead an engaging discussion about important clinical considerations for managing IBS-C in adult patients. The presentation will include interactive patient case studies, along with IBSRELA efficacy and safety data from the Phase 3 clinical trial program.
About IBSRELA® (tenapanor)
IBSRELA (tenapanor) is a locally ...